Scarica l'app Stockscreener
28.93
3.65%
1.02
Dopo l'orario di chiusura:
28.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$27.91
Aprire:
$28.41
Volume 24 ore:
960.05K
Relative Volume:
1.13
Capitalizzazione di mercato:
$1.87B
Reddito:
$32.08M
Utile/perdita netta:
$-169.77M
Rapporto P/E:
-10.18
EPS:
-2.8418
Flusso di cassa netto:
$-147.70M
1 W Prestazione:
-1.40%
1M Prestazione:
-9.96%
6M Prestazione:
-11.99%
1 anno Prestazione:
+27.22%
Intervallo 1D:
$28.36
$29.13
Intervallo di 1 settimana:
$27.66
$30.16
Portata 52W:
$20.32
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
28.93 | 1.87B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-05 | Iniziato | Guggenheim | Buy |
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics (STOK) Institutional Ownership 2026 $STOK - MarketBeat
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - manilatimes.net
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
57,784 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Deutsche Bank AG - marketbeat.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Palo Alto Investors LP Invests $2.77 Million in Stoke Therapeutics, Inc. $STOK - marketbeat.com
Jupiter Topco LLC Takes $59.36 Million Position in Stoke Therapeutics, Inc. $STOK - marketbeat.com
BlackRock Inc. Buys Shares of 5,877,357 Stoke Therapeutics, Inc. $STOK - marketbeat.com
Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight - Yahoo Finance
STOK Reinstated by JP Morgan -- Price Target Set at $40 - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Goldminenunternehmen, Ross Stores, Stoke Therapeutics - TradingView
STOK Looks 225.6% Overvalued on GF Value™ - GuruFocus
Why is Stoke Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9%What's Next? - MarketBeat
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke (STOK) Results Breakdown: The Available Earnings Metric Delivers a Miss in the Reported Period; Share Response: The Stock Records a 2.77% Increase in the Latest ReadingPerformance Review - vinanet.vn
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)? - simplywall.st
Stoke (STOK) Quarterly Figures: EPS Falls Short of Its Estimate for the Current Session; Share Move: The Stock Gains 2.64% in the Current UpdateLow Estimate Range - vinanet.vn
Stoke Therapeutics general counsel Allan sells $91,639 in stock By Investing.com - Investing.com Australia
Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ director Kaye sells $402,528 in shares By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel Allan sells $91,639 in stock - Investing.com
Stoke Therapeutics’ director Kaye sells $402,528 in shares - Investing.com
Stoke therapeutics CMO Barry Ticho sells $152k in stock - Investing.com
Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 4,767 Shares of Stock - MarketBeat
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):